Search

Author/Creator Catlett, Ian M.

2. Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*. Issue 5 (May 2019)

Authors:
Hotchkiss, Richard S.; Colston, Elizabeth; Yende, Sachin; Angus, Derek C.; Moldawer, Lyle L.; Crouser, Elliott D.; Martin, Greg S.; Coopersmith, Craig M.; Brakenridge, Scott; Mayr, Florian B.; Park, Pauline K.; Ye, June; Catlett, Ian M.; Girgis, Ihab G.; Grasela, Dennis M.
Journal:
Critical care medicine
Issue:
Volume 47:Issue 5(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants. Issue 9 (12th April 2020)

Authors:
Catlett, Ian M.; Nowak, Miroslawa; Kundu, Sudeep; Zheng, Naiyu; Liu, Ang; He, Bing; Girgis, Ihab G.; Grasela, Dennis M.
Journal:
British journal of clinical pharmacology
Issue:
Volume 86:Issue 9(2020)
Page Start:
1849
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗